Artificial intelligence (AI) is transforming antibody discovery by enabling researchers to design and optimize thousands of antibody sequences in a fraction of the time required by traditional approaches. However, while computational design has become increasingly efficient, experimental validation has struggled to keep pace.
AI-driven antibody discovery has made it possible to generate thousands of candidate sequences in a single design cycle. However, computational predictions alone cannot confirm whether an antibody will express efficiently, bind its intended target, or demonstrate properties suitable for further development. Experimental validation remains essential.
Learn how predicted antibody structures help screen AI-designed candidates, assess CDR-H3 limits, and why wet lab validation remains essential.
Compare RushDATA Basic, Standard and Premium: BLI affinity, SPR kinetics, DSF, PSR-BVP and AC-SINS for AI-designed antibodies. Data in 2-3 days.
The 17th Annual World ADC San Diego Summit highlighted novel payload mechanisms, antibody engineering, bispecific and dual-payload ADCs, and clinical translation. Emerging strategies to improve therapeutic efficacy, overcome treatment resistance, and expand therapeutic windows were also discussed.
Recombinant antibody production involves introducing the genetic sequence encoding an antibody into a suitable expression host. The host's cellular machinery then produces the protein, which can be collected and purified for downstream analysis.
Antibody discovery has traditionally relied on screening large libraries of molecules to identify candidates that recognize a specific target. Although established techniques such as hybridoma technology and phage display have been successful, identifying and optimizing promising antibodies can require extensive experimental work.
Explore September 2026 antibody biotech deals, including major licensing agreements, ADC collaborations, bispecific antibodies, AI drug discovery, and financing rounds.
As AI models become more involved in antibody discovery and design, the need for reliable experimental data is growing. Turning predicted sequences into structured, comparable assay results is an important step towards connecting computational predictions with laboratory evidence.Antibody design is
Recap of Antibodies After Hours Boston 2026: IPI's DELPHI developability prediction, CDR H3 polyreactivity insights, and Biointron's RushDATA™ wet-lab platform.
Key trends from the 17th World Bispecific Summit 2026 in Boston: AI-guided design, CD2/CD28 T-cell engagers, conditional antibodies, multispecific ADCs.
Biointron’s Antibodies After Hours: From Algorithms to Antibodies was held at The Hangar in South San Francisco, on Friday, September 4, 2026. “Antibodies After Hours” is a networking reception series from Biointron held in biotech hubs across the United States, with events previously hosted in S